1 The hypoglycaemic and hypoketonaemic effects of orally administered methyl palmoxirate were studied in streptozotocin/alloxan-induced diabetic dogs. 2 Single oral 50mg doses (-7.5mgkg-1) of methyl palmoxirate produced statistically significant reductions of plasma glucose (32 + 6% maximum reduction from baseline) and ketones (74 + 12% maximum reduction from baseline), with the peak effect on plasma ketones (3.5 h) preceding that for plasma glucose (6.0 h). 3 Lower doses (0.7-2.0mg kg' daily) of methyl palmoxirate given repeatedly for seven days produced reductions of blood glucose and ketones equivalent to those produced with the higher single dose. Maximal reductions of plasma ketones were generally observed following the first dose of drug, whereas significant lowering of plasma glucose required several days of continuous dosing. 4 Repeated daily doses of methyl palmoxirate markedly reduced the overnight fasting ketone levels but not glucose levels of diabetic dogs. 5 In conclusion, administration of the fatty acid oxidation inhibitor methyl palmoxirate, in the absence of concomitant insulin therapy, was able to lower the plasma glucose and ketone levels of insulin-deficient streptozotocin/alloxan diabetic dogs. Only the plasma ketones were decreased to normal by this treatment.
Introduction
Methyl palmoxirate (Me-TDGA, methyl 2-tetradecylglycidate), is a potent, specific, irreversible inhibitor of the mitochondrial enzyme carnitine palmitoyltransferase (CPT-A) (Tutwiler & Ryzlak, 1980; Kiorpes et al., 1984) and of long-chain fatty acid oxidation (Tutwiler et al., , 1981 Tutwiler & Dellevigne, 1979) . Me-TDGA is an orally effective hypoglycaemic and hypoketonaemic agent in fasted nondiabetic and diabetic animals (Tutwiler et al., 1978; 1981; 1983 ; Lee et al., 1982) and in preliminary studies in diabetic patients (Mandarino et al., 1984; Verhaegen et al., 1984) . In 48-h fasted nondiabetic rats, plasma ketones and liver mitochondrial CPT-A activity were previously shown to be significantly decreased following single oral doses of Me-TDGA (0.05-0.25mgkg-1) that were 10 to 25 fold less than those required for consistent inhibition 1 Author for correspondence.
of muscle CPT-A activity and lowering of blood glucose (Brentzel et al., 1982; Tutwiler et al., 1985) . Furthermore, studies in nondiabetic rats showed that repeated daily dosing (3 days) with Me-TDGA produced greater hypoglycaemic efficacy than single doses (Tutwiler et al., 1981) . These studies were performed to compare the effects of single (7.5 mg kg-') versus multiple oral doses (0.1-2.Omgkg-1) of methyl palmoxirate in a diabetic animal model (streptozotocin/alloxan-induced diabetic dogs).
Methods

Animals
Mongrel dogs (8-12 kg) were fed a high protein diet (34% protein, Hill's Science Diet) with water available ad libitum. Diabetes was induced by intravenous injection of streptozotocin (20-30mgkg-1, Upjohn Co.) and alloxan (30-5Omgkg-1, Sigma Chemical Co.) and dogs were stabilized for 3-4 weeks before use (Black et al., 1980) . Dogs fasted for 18h were used for study.
Blood samples (5-10 ml), obtained from the jugular vein in heparinized Vacutainers at specified times after dosing, were centrifuged and the plasma removed. Plasma glucose concentrations were determined by the automated (Gilford Model 203 Clinical Analyzer) hexokinase method (Statzyme, Worthington Diagnostics, Inc.). Plasma ketones (fihydroxybutyrate and acetoacetate) were measured on protein-free filtrates by use of a coupled enzymatic assay (enzymes purchased from BoehringerMannheim) described previously (Tutwiler et al., 1978; .
Experimental protocols
Single dose studies Blood samples were obtained from eight diabetic dogs immediately before dosing (-15 and 0min) , and again at 1, 2, 3, 4, 5, 6, 9 and 24 h after dosing for determination of plasma glucose and ketones (fl-hydroxybutyrate and acetoacetate).
Repeat dose studies Two experimental protocols were used. Because the diabetic state was variable among dogs, a placebo-drug-placebo experimental design was used.
Protocol I Diabetic dogs (n = 5) were dosed orally with placebo on day 1 followed by Me-TDGA (5-0 mg total dose) given once-a-day for seven consecutive days (day 2 through day 8). After seven treatment days, all dogs were given placebo for eight additional days. On days 1, 2, 3, 5, 8 and 16, blood samples were obtained before dosing (-15 consecutive days, progressing from 0.1 mg kg -1 daily to a maximum dose of 2.0 mg kg-1 daily followed by placebo treatment for an additional 7 to 14 days. In three other dogs, after placebo treatment for two days, Me-TDGA was administered at 0.8 and 2.0mg kg 1 daily for seven consecutive days at each dose, followed by placebo treatment for eight days. During placebo treatment and on days 1, 3 and 7 of drug-treatment, blood samples were obtained prior to dosing (-15 and 0min) and at 3 and 6h after dosing. On days 2,4 and 6 of each treatment period, only morning baseline fasting blood samples were obtained (i.e., 24 h after the preceding day's dose).
Drug preparation
Methyl 2-tetradecylglycidate (Me-TDGA; generic name: methyl palmoxirate), synthesized as previously described (Tutwiler et al., 1981) , was given as soft gelatin capsules containing either 5mg or 50mg of Me-TDGA formulated in 180mg neutral oil + 600mg Tween 80 as vehicle (prepared by R.P. Scherer Co.). In one repeat dose study (Protocol II), hard gelatin capsules containing the desired amount of the drug on a mgkg-1 body weight basis were prepared using the Scherer vehicle. Me-TDGA has been shown to be stable under these conditions of formulation. Capsules containing vehicle were used as placebo. The actual dose of Me-TDGA delivered (mg kg-') was calculated for each dog using the pretest body weight.
Statistics
Data are presented as mean (± s.e. mean) concentrations (mg dl-1 and mm for glucose and ketones, respectively) and as the percentage lowering from daily baseline. The maximum percentage reduction from daily baseline was calculated for each dog and averaged to yield mean maximum percentage reductions from baseline (+s.e. mean). Data were statistically analyzed using Dunnett's t test for multiple comparisons after one-way analysis of variance or, where appropriate, by the paired Student's t test.
A P value of 0.05 or less was considered to be statistically significant.
Results
Single dose studies A single oral dose of Me-TDGA (mean of 7.5mg kg-1, range of 5 to 10mgkg-') produced statistically significant reductions of plasma glucose and ketones (Table 1) , with mean maximum % reductions from baseline of 32 + 6% and 74 + 12%, respectively. Maximal reductions of plasma ketones (mean time of 3.5 + 0.3 h) preceded the maximal reductions of plasma glucose (mean time of 6.0 + 1.0 h). Plasma ketone levels were in the normal range by 2 h post-dosing and were maintained during at least 9 h post-dosing. Although not statistically significant, plasma ketones were still reduced by 31% at 24 h after dosing, whereas fasting plasma glucose had returned to baseline levels.
Repeat dose studies Protocol I Lower oral doses of Me-TDGA given repeatedly to diabetic dogs for seven days (mean dose of 0.7mg kg-daily for 7 days) produced significant reductions of plasma glucose and flhydroxybutyrate levels (Table 2) . Following the first dose (day 2) of Me-TDGA, plasma flhydroxybutyrate levels were markedly decreased and these reductions from daily baseline were maintained with continued dosing. In contrast, the mean plasma glucose levels were only modestly decreased (9 + 3%) following the first dose of Me-TDGA (Table 2) . With continued dosing however, the magnitude of the plasma glucose reduction progressively increased, with a mean maximal reduction of 30 + 5% achieved following the seventh dose of drug (day 8). Continued Me-TDGA treatment qualitatively improved glycosuria and ketonuria, which returned to predrug levels after eight days of placebo treatment (data not shown). The drug effect on plasma glucose did not carryover to the next day, since the daily baseline fasting glucose level (i.e., 24h after the previous dose) was not significantly different from that on the previous day nor was there a trend for improvement of overnight fasting plasma glucose with continued dosing (Table 2) . Repeated daily dosing with Me-TDGA did, however, markedly lower (76% reduction, day 8 vs day 1) the overnight fasting plasma flhydroxybutyrate levels (Table 2) , which returned to predrug levels following eight consecutive days of placebo treatment.
Protocol II The antiketonaemic and hypoglycaemic effects of lower repeated doses of Me-TDGA, were evaluated in diabetic dogs which began treatment either at 0.1mgkg-1 or at 0.8mgkg-' daily and progressed to a maximum dose of 2.0mgkg-1 daily for seven days (Figures 1 and 2 respectively) . At repeated doses of 0.1 to 0.4 mg kg'-daily, Me-TDGA produced small, statistically nonsignificant reductions of plasma glucose and ketones from daily baseline (Figure 1) . At higher doses of 0.6 to 2.0mg kg-' daily, Me-TDGA effectively lowered plasma ketone levels ( Figures 1 and 2) ; however, statistically significant reductions of plasma glucose were only achieved at the 2.0mgkg-t daily dose in one study (Figure 1 ). At doses of 0.8 and 2.0 mg kg-1 daily, the mean fasting plasma ketone level measured 24h after the previous day's dose was significantly lowered (6.45 + 0.97 to 1.81 + 0.47 mM, n = 3, P < 0.05), whereas the mean fasting plasma glucose level was unchanged with continued dosing. After placebo treatment for one to two weeks, fasting plasma ketones returned to predrug levels (5.80 + 0.67 mM). 
Discussion
The hypoglycaemic and hypoketonaemic effects of the fatty acid oxidation inhibitor Me-TDGA were studied in an insulin-deficient diabetic dog model following either oral administration of repeated lower doses (0.1-2.0 mg kg-daily) or a higher single dose (7.5 mg kg-1).
We have shown that repeated administration of lower doses (0.7 to 2.Omgkg-' daily for seven days)
of Me-TDGA to diabetic dogs produced reductions of blood glucose and ketones that were quantitatively similar to those produced by a higher single dose (7.5 mgkg-1 (Tutwiler et al., 1985) . Our current belief is that the blood glucose reduction observed in fasted nondiabetic rats following oral administration of single higher doses (>2.5mg kg-1) of Me-TDGA is due to the ability of the drug to stimulate peripheral glucose utilization (Tutwiler et al., 1981; Tuman et al., 1987) and, that the ability of Me-TDGA to inhibit hepatic gluconeogenesis is not, by itself, sufficient to contribute significantly to glucose reduction. This idea is further supported by the observation in nondiabetic rats that peripheral skeletal muscle mitochondrial CPT-A activity was significantly inhibited only with acute oral doses of Me-TDGA greater than 2.5mg kg-1 (Tutwiler et al., 1985) . Furthermore, isotopic glucose studies in diabetic dogs suggest that repeated low oral doses of Me-TDGA (2-3mg kg-1) lower fasting plasma glucose both by enhancing peripheral tissue glucose clearance and by decreasing hepatic glucose production, with the latter activity being important only in dogs having elevated hepatic glucose output (unpublished data). It is probable that in these diabetic dogs, as in nondiabetic rats, peripheral muscle CPT-A activity is not sufficiently inhibited by low oral doses (0.1-0.6mgkg-1 daily) of Me-TDGA, and only after repeated administration of higher doses (0.7-2.0mgkg-', daily) of this irreversible inhibitor is muscle CPT-A activity sufficiently inhibited and peripheral glucose utilization sufficiently stimulated to impact circulating blood glucose levels. Thus, the irreversible nature of the inhibition may produce a sustained block of peripheral CPT-A enzyme activity and long-chain fatty acid oxidation which could result in progressively greater blood glucose reduction with continued dosing. This hypothesis will have to be tested in further studies, since peripheral CPT-A activity and peripheral glucose utilization were not determined in these dogs. An alternative possibility is that the reduction in blood glucose observed following multiple low doses was produced by an accumulation of drug with continued dosing. We cannot exclude this possibility since an adequate analytical method to determine blood levels of Me-TDGA is not available.
In summary, Me-TDGA was shown to be an orally effective hypoglycaemic and hypoketonaemic agent in insulin-deficient diabetic dogs. The therapeutic significance of this activity has been demonstrated in preliminary studies in diabetic patients (Mandarino et al., 1984; Verhaegen et al., 1984) .
